Skip to main content

Table 1 Clinical baseline characteristics of the participants

From: Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis

Parameter Total (n = 11) Responder (n = 8) Non-responder (n = 3)
Gender    
 Female 7 (64%) 5 (62%) 2 (67%)
 Male 4 (36%) 3 (38%) 1 (33%)
Age 33.6 ± 10.5 29.6 ± 9.2 44.3 ± 8.0
  (19.0 to 55.0) (19.0 to 47.0) (39.0 to 55.0)
Body mass index 25.5 ± 3.0 22.9 ± 2.6 26.2 ± 4.0
  (20.1 to 30.7) (22.0 to 30.7) (20.1 to 25.7)
Relapse rates in the past 12 months (median and range) 2 2 1
  (1 to 4) (1 to 4) (1 to 2)
Baseline Expanded Disability Status Scale 4 3.5 4
  (2 to 7.5) (2 to 7.5) (3 to 4)
Days after onset of relapse 26.6 ± 14.6 29.3 ± 15.6 19.3 ± 10.1
  (10.0 to 60.0) (10.0 to 60.0) (10.0 to 30.0)
Days after initiation of corticosteroid therapy 10.8 ± 6.9 12.3 ± 6.6 7.0 ± 7.2
  (1.0 to 20.0) (3.0 to 20.0) (1.0 to 15.0)
Cumulative dose of prednisolone equivalents (g) 9.5 ± 3.7 8.6 ± 3.7 12.0 ± 2.6
  (4.0 to 15.0) (4.0 to 15.0) (10.0 to 15.0)
Duration of disease (years) 3.5 ± 4.9 5.7 ± 2.9 2.7 ± 9.0
  (0.0 to 16.0) (0 to 7.0) (0.0 to 16.0)
Initial disease modifying therapy 3 (27.3%) 2 (25%) 1 (33.3%)
 Interferon beta 2 (18.2%) 2 (25%) 0 (0%)
 Glatiramer acetate 1 (9.1%) 0 (0%) 1 (33.3%)
  1. Descriptive values are shown either as absolute numbers (frequencies) or mean ± standard deviation (minimum –maximum), except for baseline EDSS and relapse rates which are shown as medians and ranges.